Valeant Pharmaceuticals (VRX) Gains on RedHill Update

Valeant Pharmaceuticals International, Inc. VRX shares rose 0.5% to $253.08, on word that Israel-based RedHill Biopharma Ltd. provided an update on its RHB-106 tasteless solid oral formulation bowel preparation development program under the worldwide exclusive license agreement with Salix Pharmaceuticals Ltd., recently acquired by Valeant. Share volume was 62,000, compared to an all-day average of 275,000